References
- Barksdale, E., Sridhara, R., Marchenko, O., Jiang, Q., and Pazdur, R. (2021), “Summary of American Statistical Association Biopharmaceutical Section’s Virtual Discussions with Regulators on Statistical Considerations in Oncology Trials in the COVID-19 Era,” available at https://higherlogicdownload.s3.amazonaws.com/AMSTAT/fa4dd52c-8429-41d0-abdf-0011047bfa19/UploadedImages/BIOP%20Report/BioPharmSummer2021_FINAL.pdf.
- Degtyarev, E., Rufibach, K., Shentu, Y., Yung, G., Casey, M., Englert, S., Liu, F., Liu, Y., Sailer, O., Siegel, J., Sun, S., Tang, R., and Zhou, J. (2020), “Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework,” Statistics in Biopharmaceutical Research, 12, 427– 437. DOI: 10.1080/19466315.2020.1785543.
- EMA (2020), “Points to Consider on Implications of Coronavirus Disease (COVID-19) on Methodological Aspects of Ongoing Clinical Trials,” June 2020, available at https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical_en-0.pdf.
- EMA (2022), “Guidance on the Management of Clinical Trials During the Covid-19 (Coronavirus) Pandemic,” February 2022, available at https://ec.europa.eu/health/system/files/2022-02/guidanceclinicaltrials_covid19_en_1.pdf.
- EMA (2020b), “Interim Guidance for Clinical Trial Activities Affected by the Novel Coronavirus,” March 2020, available at https://ctep.cancer.gov/content/docs/Memorandum_on_Interim_Guidance_for_Clinical_Trial_Activities_Affected_by_the_Novel_Coronavirus-3-13-2020.pdf.
- EMA (2020a), “Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency FDA Guidance for Industry, Investigators, and Institutional Review Boards,” March 2020, available at https://www.fda.gov/media/136238/download.
- EMA (2020c), “Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency FDA Guidance for Industry,” June 2020, available at https://www.fda.gov/media/139145/download.
- Gerber, D. E., Clark, V. L., Sheffield, T. Y., Beg, M. S., Xie, Y., Holbein, M. E. B., Skinner, C. S., Lee, S. J. C., and Williams, E. L. (2022), “Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes,” JCO Oncology Practice, 18, e98–e107. DOI: 10.1200/OP.21.00169.
- Gerber, D. E., Sheffield, T. Y., Beg, M. S., Williams, E. L., Clark, V. L., Xie, Y., Holbein, M. E. B., Skinner, C. S., and Lee, S. J. C. (2021), “Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments,” Journal of the National Comprehensive Cancer Network: JNCCN, 19, 505–512. DOI: 10.6004/jnccn.2020.7643.
- ICH E9(R1) (2021), Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials, May E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials FDA.
- Meyer, R. D., Ratitch, B., Wolbers, M., Marchenko, O., Quan, H., Li, D., Fletcher, C., Li, X., Wright, D., Shentu, Y., Englert, S., Shen, W., Dey, J., Liu, T., Zhou, M., Bohidar, N., Zhao, P.-L., and Hale, M. (2020), “Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, 12, 399–411. DOI: 10.1080/19466315.2020.1779122.
- Williams, E. L., Pierre, D. L., Martin, M. E., Beg, M. S., and Gerber, D. E. (2021), “Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic,” JCO Oncology Practice, 17, 577–579. DOI: 10.1200/OP.21.00524.